F/m美國國庫3年期票據 ETF UTRE 深 滬
已收盤 10-16 16:00:00 美东时间
48.3281
+0.072
+0.15%
華盛通- 最 高48.34
- 今 開48.34
- 成交量 2011股
- 最 低 48.3281
- 昨 收 48.2564
- 總市值 1063.22万
- 52周最高 48.8749
- 市盈率 靜 --
- 換手率 0.91%
- 52周最低 47.8834
- 委 比 0.00%
- 總股本 22.00万
- 歷史最高 48.8749
- 量 比 0.11
- 振 幅 0.02%
- 歷史最低 42.5556
- 每 手 1
- 風險率 0.20%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Liquidia rockets 42% as $380.7M deal ends United Therapeutics legal battle
Liquidia (LQDA) shares jumped 42% after the company reached a $380.7M settlement with United Therapeutics (UTHR), resolving six ongoing lawsuits and securing continued commercialization of YUTREPIA fo...
10-14 13:06
Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics, Ensuring Continued Commercialization of YUTREPIA in PAH
Liquidia Corporation and United Therapeutics Corporation have reached a global settlement resolving all six ongoing lawsuits. YUTREPIA® for PAH patients remains available. Liquidia will pay $380.7 million in installments by 2027. Q3’26 YUTREPIA sales were $222.7 million, with $396.1 million in cash. Liquidia will continue advancing YUTREPIA and L606 programs.
10-13 21:44
Liquidia Gains FDA Fast Track for YUTREPIA in Raynaud’s
Liquidia Technologies ( ($LQDA) ) has provided an announcement. On September 3,...
09-03 20:51
These Treasury ETFs offer low-cost exposure as investors navigate rates
As investors continue to assess the direction of interest rates and the outlook for the U.S. Treasury market, exchange-traded funds offer a relatively low-cost way to gain exposure across different ma...
08-24 21:15
Liquidia (LQDA) 2026年第二季度业绩电话会议：YUTREPIA销售额增长31%
Liquidia 的 2026 年第二季度业绩电话会议涵盖了 YUTREPIA 达 1.704 亿美元的销售额、31% 的季度增长、利润上升、管线支出及其 2027 年目标。
08-14 08:27
Liquidia Reports Strong Q1 Profitability Driven by YUTREPIA
An announcement from Liquidia Technologies ( ($LQDA) ) is now available. Liquid...
05-11 19:21
Liquidia Analysts Boost Their Forecasts After Q4 Earnings
Liquidia Corp (LQDA) reported mixed Q4 results, with earnings missing estimates but sales beating expectations. Analysts have mixed opinions on stock.
03-07 00:17
Demystifying Liquidia: Insights From 7 Analyst Reviews
Across the recent three months, 7 analysts have shared their insights on Liquid...
03-06 21:00
